HopeStage
Back to all studies
CompletedNCT05322941

AEF0117 medication research for people with cannabis use concerns

About this title

Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)

Read the official source — NCT05322941
Medication studyAges 18–65United StatesAddiction
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
Phoenix and 10 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: May 6, 2022
Recruitment status
Completed
Enrollment listed in the registry
333
Sponsor
Aelis Farma
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT05322941
Official title
Show the full official title

A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group, Phase 2b Study in Treatment-seeking Patients With Cannabis Use Disorder to Assess the Efficacy, Safety, and Tolerability of AEF0117 in Reducing Cannabis Use

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Phoenix · Garden Grove · Los Angeles

8 more locations
  • New Haven
  • Lauderhill
  • Miami Lakes
  • New York
  • Portland
  • Charleston
  • San Antonio
  • Draper

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Aelis Farma.

Did this study involve medication?

Yes. The study involved medication, including AEF0117 and Placebo oral capsule.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies